Show
Sort by
-
MP29-02* provides effective AR symptom control in real life regardless of number of previous clinic visits : results from Germany
-
MP29-02* provides effective relief in real life in all patients regardless of ARIA-defined severity : results from Germany
-
MP29-02* provides effective relief in real life in patients previously treated with mono- and multiple-therapy : results from Germany
-
MP29-02* provides effective AR symptom control in real life in previous or potential treatment failure patients : results from Germany
-
MP29-02* provides effective AR symptom control in real life in all patient types regardless of predominant nasal symptom or presence of ocular symptoms: results from Germany
-
Real-world effectiveness of a new allergic rhinitis therapy (MP29-02)
-
A new allergic rhinitis therapy (MP29-02) is more effective than current first line monotherapies in providing allergic rhinitis patients relief from their nasal and ocular symptoms (rTNSS, rT5SS, rT7SS)
-
Development and implementation of guidelines in allergic rhinitis: an ARIA-GA2LEN paper
-
Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells
-
Present role of sublingual immunotherapy in allergic diseases
-
Efficacy and safety of montelukast in adults with asthma and allergic rhinitis
-
Interleukin-5 receptors on human lung eosinophils after segmental allergen challenge